abstract: BACKGROUND: Time to treatment of @entity1 is becoming a serious political and social issue. A greater understanding of the timeframes involved in @entity1 care is needed to reduce inequalities in access to care caused by delays. OBJECTIVE: To describe indicators of time to first treatment after colonoscopy in @entity4 ( @entity4 ) and @entity3 ( @entity3 ) @entity0 in France. METHOD: Using the international classification of diseases and medical procedures codes, from national hospital discharge and long term illness databases we selected @entity0 newly diagnosed for @entity4 or @entity3 in 2009-2010 who had undergone treatment. RESULTS: We included 15 694 and 6 623 @entity0 for @entity4 and @entity3 , respectively. Median times to surgery in @entity0 with a surgical treatment pathway for @entity4 and @entity3 were 22 (Q1=14; Q3=34) and 97 (Q1=34; Q3=141) days, respectively. Median times to chemotherapy for @entity0 with a non-surgical treatment pathway, for @entity4 and @entity3 were 36 (Q1=21; Q3=59) and 40 (Q1=27; Q3=59) days, respectively. The median time to radiotherapy in @entity3 @entity0 was 53 (Q1=39; Q3=78) days.Time to surgery as first treatment in @entity3 @entity0 (46 days) was twice as long as that in @entity4 @entity0 (22 days). Time to treatment was longer in most northern regions and in overseas districts, and shorter in southern regions, for both @entity4 and @entity3 . CONCLUSION: The findings in this unprecedented study in France will inform decision-making policies on the future implementation of guidelines on timeframes for @entity2 treatment access.

title: Time to first treatment after colonoscopy in XXXX suffering from @entity4 in France.

answer: @entity0


abstract: BACKGROUND: The efficiency and safety of dorsal rhizotomies for @entity2 lie in the accuracy of radicular identification together with selectivity of root sectioning. Two different exposures are currently in use. The first is extended laminotomy/laminectomy from the upper lumbar level to the sacrum, which allows accurate identification of all L2-S2 roots/rootlets. The second is limited laminotomy exposing the conus/cauda equina at the thoracolumbar junction; this less invasive method limits accessibility to the roots. To optimize the accuracy and selectivity while minimizing invasiveness, the authors developed a tailored interlaminar procedure targeting the radicular levels involved in the harmful components of @entity3 directly and individually. METHODS: Six @entity0 with @entity2 at different levels of the Gross Motor Functional Classification System were selected. In each @entity0 , two to three interlaminar spaces, preselected according to planning, were enlarged in the "keyhole" fashion, respecting the spinous processes and interspinous ligaments. Ventral root stimulation identified the radicular level. Dorsal root stimulation evaluated its implication in the hyperactive segmental circuits, helping quantify the percentage of rootlets to be cut. RESULTS: There were neither wound-related nor general complications. At 1 year of follow-up, X-ray examination did not reveal @entity4 or instability. In all @entity0 , the excess of @entity3 was reduced. The Ashworth score decreased from 3.2 on average to 0.6 postoperatively (range: 2-4 to 0-2). Regarding the functional status at 1 year of follow-up for the three ambulatory @entity0 , the Gillette ability-to-walk score increased from 3/10 on average to 7.3/10 postoperatively (range: 2-4 to 7-8). For the three non-ambulatory @entity0 , abnormal postures, @entity1 and ease of care were much improved. CONCLUSION: Keyhole interlaminar dorsal rhizotomy (KIDr) offers direct intradural access to each of the ventral/dorsal roots, thus maximizing the reliability of anatomical mapping and allowing individual physiological testing of all targeted roots. The interlaminar approach minimizes invasiveness by respecting the posterior spine structures.

title: Keyhole interlaminar dorsal rhizotomy for @entity2 in XXXX .

answer: @entity2


abstract: UNASSIGNED: Background: @entity1 ( @entity1 ) from @entity3 ( @entity3 ) is a rare entity. This study aimed to assess the outcomes of @entity3 @entity0 presenting with @entity1 after total thyroidectomy and radioactive iodine therapy. Methods: A total of 5367 @entity3 @entity0 treated with (131)I after total thyroidectomy were analyzed retrospectively from January 1991 to June 2013. Therapeutic efficacy was evaluated based on changes in serum @entity7 (Tg) and anatomical imaging changes in metastatic lesions. The relationships between survival time and several variables were assessed by univariate and multivariate analyses using the Kaplan-Meier method and Cox's proportional hazards model respectively. Results: Thirty-eight @entity0 with @entity1 from @entity3 were diagnosed, including four with @entity5 , four with @entity5 , and three with @entity4 . The remaining 27 were euthyroid. Of 25 @entity0 with lung @entity1 , 84% (21/25) showed disappearance or shrinkage of lung nodules; of 24 @entity0 with bone @entity1 , 66.67% (16/24) exhibited no obvious imaging changes in metastatic @entity2 after (131)I therapy. Serum Tg decreased significantly in 81.58% (31/38) and increased in 18.42% (7/38) after (131)I therapy. The 10-year survival rate of @entity3 @entity0 with @entity1 was 65.79% (25/38). Multivariate analyses identified age at occurrence of distant @entity1 (<45 years), only lung @entity1 , and @entity6 ( @entity6 ; p=0.032, NA, and 0.043) as independent predictors of survival. Conclusion: The response of hyperfunctioning lung @entity1 to (131)I treatment was better than that of non-hyperfunctioning lung @entity1 in @entity3 , while hyperfunctioning bone @entity1 responded similarly compared to non-hyperfunctioning bone @entity1 . @entity0 younger than 45 years at occurrence of distant @entity1 , those with only lung @entity1 , and @entity0 with @entity6 had better prognoses.

title: Clinical Management and Outcomes in XXXX with Hyperfunctioning Distant Metastases from Differentiated @entity3 After Total Thyroidectomy and Radioactive Iodine Therapy.

answer: @entity0


abstract: BACKGROUND: To assess the efficacy of oral microemulsion @entity4 (CyA Neoral) in the treatment of @entity3 -refractory attacks of ulcerative an @entity8 . METHODS: In this non-randomized study on the use of oral microemulsion @entity4 in @entity3 refractory @entity1 , we used CyA Neoral in 10 @entity0 suffering from @entity1 and in 1 @entity0 suffering from @entity8 with a @entity3 -refractory attack. The initial dose was 7-7.5 mg kg-1 day-1 adjusted to maintain whole blood @entity4 levels between 250 and 350 ng/mL, as measured by RIA using monoclonal antibodies. RESULTS: Nine @entity0 presented a favourable response in a mean time of 3.6 days, that is, 81.8% of cases. One initial responder developed @entity7 on the 11th day and another did not respond; surgical treatment was performed in both cases. The remaining nine @entity0 , followed for a mean period of 14.6 months (2-36 months). Nine @entity0 presented side effects, the most frequent being slight hand @entity5 with hypomagnesaemia, followed by @entity2 , slight increase in @entity6 and hirsutism. No one needed to withdraw from treatment, but the dose was lowered in three cases. CONCLUSIONS: Oral microemulsion @entity4 is an effective drug in the initial management of @entity0 suffering from a @entity3 -refractory attack of ulcerative and @entity8 . Additional controlled studies with the new oral formulation are required to confirm these results.

title: Oral microemulsion XXXX in the treatment of @entity3 -refractory attacks of ulcerative and @entity8 .

answer: @entity4


abstract: Dysregulation of microRNAs (miRNAs) has been found to be associated with a variety of diseases, including @entity2 ( @entity2 ). Recently, @entity5 was reported to be downregulated in @entity0 @entity2 , however, the clinical significance and functional roles of @entity5 expression in @entity0 @entity2 are unclear. TaqMan real-time quantitative RT-PCR assay was performed to detect the expression of @entity5 in 98 @entity2 tissues and 15 adjacent normal epithelial tissues. The relationship between @entity5 expression and clinicopathological factors in 98 @entity2 @entity0 was statistically analyzed. The effect of @entity5 expression on @entity0 survival was determined. Finally, the role of @entity5 in @entity2 cell growth and its possible mechanisms were analyzed with @entity5 precursor or inhibitor-transfected cells. We showed that the level of @entity5 was significantly lower in @entity2 tissues compared to adjacent normal tissues. Low @entity5 expression was found to be closely correlated with advanced FIGO stage, higher serum @entity4 expression level and lymph node involvement. Also, low @entity5 expression was correlated with shorter overall survival of @entity2 @entity0 , and multivariate analysis showed that the status of @entity5 expression was an independent predictor of overall survival in @entity2 . Additionally, @entity5 could affect the growth of @entity2 cells by post-transcriptionally regulating @entity3 ( @entity3 ) expression. Together, these results suggest that low @entity5 expression may be an independent poor prognostic factor and @entity5 can function as a @entity1 suppressor by targeting @entity3 in @entity0 EOCs.

title: Prognostic implications of microRNA-100 and its functional roles in @entity0 XXXX .

answer: @entity2


abstract: BACKGROUND: The optimal means of achieving therapeutic oral anticoagulation in the outpatient setting has not been determined. OBJECTIVE: To compare a 10-mg dosing nomogram with a 5-mg nomogram that has been suggested to be sufficient for @entity3 initiation. DESIGN: Randomized, controlled clinical trial. SETTING: Outpatient @entity2 services of four tertiary care hospitals. @entity0 : 201 of 210 consecutive @entity0 with objectively confirmed diagnoses of @entity2 . INTERVENTION: All @entity0 were treated with subcutaneous low-molecular-weight heparin for a minimum of 5 days until a therapeutic international normalized ratio (INR) was achieved. @entity0 were randomly assigned to initially receive a 10-mg or 5-mg dose of @entity3 . MEASUREMENTS: The primary end point was time in days to therapeutic INR. Secondary end points were the proportion of @entity0 who had achieved a therapeutic INR by day 5, the total number of INR assessments, the number of INR measurements greater than 5.0, incidence of recurrent @entity2 and @entity1 , and survival. RESULTS: 210 consecutive @entity0 met the inclusion criteria. Of these, 9 were excluded and 201 were randomly assigned to study groups (104 to the 10-mg group and 97 to the 5-mg group). Demographic characteristics of both groups were similar. @entity0 in the 10-mg group achieved therapeutic INR 1.4 days earlier than @entity0 in the 5-mg group (P < 0.001). Eighty-three percent of @entity0 in the 10-mg group achieved a therapeutic INR by day 5 versus 46% in the 5-mg group (P < 0.001). Fewer INR assessments were performed in the 10-mg group than in the 5-mg group (8.1 vs. 9.1; P = 0.04). There were no significant differences between the two groups in recurrent events, @entity1 , survival, and number of INR measurements greater than 5.0. CONCLUSION: The 10-mg @entity3 initiation nomogram is superior to the 5-mg nomogram because it allows more rapid achievement of a therapeutic INR.

title: Comparison of 10-mg and 5-mg XXXX initiation nomograms together with low-molecular-weight heparin for outpatient treatment of @entity2 . A randomized, double-blind, controlled trial.

answer: @entity3


abstract: BACKGROUND: Data on routine systemic treatment of @entity0 with @entity1 are currently available only to a limited degree. The alkylating agent @entity3 is approved in oral (p.o.) and intravenous (i.v.) form for the treatment of @entity1 . The present non-interventional study analyzed the clinical use of @entity3 in Germany, evaluating the mode of application, @entity2 , and response and survival rate. @entity0 AND METHODS: Two hundred and forty-eight @entity1 @entity0 in 57 Centers, who received @entity3 mainly either i.v. (5,000-8,000 mg/m(2) d1, q21d or q28d) or p.o. (400-600 mg/m(2) d1-14 or 21, q28d) for at least one therapy cycle were evaluable and were included in the study. RESULTS: With a median age of 70 years (range=36-92 years), predominantly elderly @entity0 received @entity3 treatment. Most @entity0 presented serous histology (131, 52.8%) and advanced-stage FIGO III (122, 49%) or IV (55, 22%) disease. Median ECOG status was 1 (range=0-2), whereas cardiac co-morbidity was common (31%). @entity3 was usually administered as second- (26%), third- (21%) or fourth-line (17%) therapy. Two hundred and one @entity0 received i.v. and 47 p.o. TREATMENT: The most common reason for dose modifications was due to hematological @entity2 (46%). The main reason for a therapy discontinuation was progressive disease (38.5%). Response was observed in 25.8% of @entity0 , disease stabilization in 28.6 % and progress in 45.6%. The median progression-free and overall survival was 196 and 405 days, respectively. CONCLUSION: In predominantly elderly and heavily pre-treated @entity0 with recurrent @entity1 , @entity3 featured a clinical relevant efficacy and well-manageable, mostly hematological, @entity2 , which resulted in a positive therapeutic index.

title: XXXX in the Treatment of Advanced @entity1 - Results of a German Multicenter Non-interventional Study.

answer: @entity3


abstract: BACKGROUND AND METHODS: Mass @entity3 may be difficult to differentiate from illness caused by bioterrorism, rapidly spreading infection, or toxic substances. We investigated symptoms attributed to exposure to toxic gas at a high school in Tennessee. In November 1998, a teacher noticed a 'gasoline-like' smell in her classroom, and soon thereafter she had a @entity1 , @entity5 , @entity8 , and @entity7 . The school was evacuated, and 80 students and 19 staff members went to the emergency room at the local hospital; 38 @entity0 were hospitalized overnight. Five days later, after the school had reopened, another 71 @entity0 went to the emergency room. An extensive investigation was performed by several government agencies. RESULTS: We were unable to find a medical or environmental explanation for the reported illnesses. The @entity0 who reported symptoms on the first day came from 36 classrooms scattered throughout the school. The most frequent symptoms (in this group and the group of @entity0 who reported symptoms five days later) were @entity1 , @entity7 , @entity5 , and drowsiness. Blood and urine specimens showed no evidence of @entity6 , volatile organic compounds, pesticides, @entity9 , @entity10 , or @entity4 . There was no evidence of toxic compounds in the environment. A questionnaire administered a month later showed that the reported symptoms were significantly associated with female sex, seeing another ill @entity0 , knowing that a classmate was ill, and reporting an unusual odor at the school. CONCLUSIONS: The illness attributed to toxic exposure had features of mass @entity3 - notably, widespread subjective symptoms thought to be associated with environmental exposure to a toxic substance in the absence of objective evidence of an environmental cause. Alleviation of the @entity2 surrounding an episode of mass @entity3 requires prompt recognition and a detailed investigation.

title: Mass XXXX attributed to toxic exposure at a high school.

answer: @entity3


abstract: BACKGROUND: @entity7 ( @entity8 ) is a neural stimulant agent, which its neurochemical and behavioral effect remain unclear. @entity5 is a @entity4 - @entity6 reuptake inhibitor @entity9 , which was used for management of @entity3 and @entity2 . In this study, protective effects of @entity5 on @entity8 induced @entity2 , @entity3 and @entity1 were investigated. METHODS: Forty-eight adult male @entity0 were divided randomly to 5 groups. Group 1, received normal saline (0.2 ml/ @entity0 ) for 21 days and served as control group. Group 2, received @entity8 (10 mg/kg) for 21 days. Groups, 3, 4, 5 and 6 concurrently were treated by @entity8 (10 mg/kg) and @entity5 at doses of 25, 50, 75 and 100 mg/kg respectively for 21 days. On day 22, elevated plus maze (EPM), open field test (OFT), forced swim test (FST) and tail suspension test (TST) were used to investigate the level of @entity2 and @entity3 in animals. In addition, between days 17 and 21, Morris water maze (MWM) was used to evaluate the effect of @entity8 on spatial learning and memory. RESULTS: @entity8 caused @entity3 and @entity2 in a dose-dependent manner in FST, OFT, EPM and TST, which were significantly different compared with control group. Furthermore, @entity8 can significantly attenuate the motor activity in OFT. @entity5 in all doses can attenuate @entity8 induced @entity2 , @entity3 and motor activity alterations. @entity8 also can disturb learning and memory in MWM, but @entity5 did not alter this effect of @entity8 . CONCLUSIONS: We conclude that @entity5 can be protective in the brain against @entity8 induced @entity2 and @entity3 .

title: Reduction of @entity7 Induced @entity2 , @entity1 by Various doses of @entity5 in XXXX .

answer: @entity0


abstract: CONTEXT: Kidney, prostate, and @entity3 increase with age and are influenced partly by modifiable risk factors. @entity1 rates may increase substantially amid a growing, aging population. OBJECTIVE: To describe kidney, @entity5 incidence, mortality, and risk factor-attributable bladder and @entity6 @entity4 between 1990 and 2013, by age, sex, and development status. EVIDENCE ACQUISITION: @entity1 mortality data were derived from global vital registries. Incidence data from @entity1 registries were transformed to mortality estimates using separately estimated mortality incidence ratios. These sources served as input data for an ensemble modeling approach to estimate bladder, prostate, and @entity6 mortality. Cause-specific mortality estimates were transformed into incidence estimates using mortality incidence ratios. EVIDENCE SYNTHESIS: In 2013, 2.1 million kidney, @entity5 cases occurred worldwide, increasing 2.5-fold since 1990. Mortality increased 1.6-fold between 1990 and 2013. Eight-two percent of new cases in 2013 occurred in individuals aged 60 yr and older. @entity0 from developed countries had the highest age-standardized @entity4 rates among all three @entity1 . Smoking-attributable @entity6 @entity4 decreased while @entity2 -related @entity4 rose, most prominently in @entity0 from developing countries. Smoking-related @entity3 @entity4 increased among @entity0 from developed countries and decreased among @entity0 . CONCLUSIONS: @entity1 burden has increased globally amid population growth and aging. High income countries face the highest incidence and @entity4 rates; however, @entity2 -attributed @entity6 @entity4 are increasing in developing countries. Efforts to expand the global oncologic workforce and reduce preventable factors may lessen @entity1 disparities in developing countries. @entity0 SUMMARY: We describe the impact of population growth, aging, and lifestyle factors such as smoking and @entity2 , on kidney, @entity5 rates worldwide. More new @entity1 cases and @entity4 occur in developed countries compared with developing countries. In addition to preventive efforts, healthcare systems must emphasize training of a urologic oncology workforce.

title: Global Burden of XXXX , 1990-2013.

answer: @entity1


abstract: OBJECTIVES: Treatment of choice at stable @entity3 is still a matter of debate. The aim of this study is assessment of health-related quality of life (HRQOL) regarding short form-36 (SF-36) and its correlation with @entity4 in @entity0 affected by thoracolumbar @entity3 without @entity1 undergoing posterior short segment pedicular screw fixation. MATERIALS AND METHODS: Twenty @entity0 with thoracolumbar @entity3 without @entity1 , meeting our criteria were enrolled in this study. The @entity0 underwent short segment pedicular screw fixation. After 2 years of follow-up, the outcome assessment was performed with evaluating HRQOL; SF-36. The mean    standard deviation was measured at each eight category of SF-36 and compared with normative values of Iran. The correlation of Cobb angle and @entity2 was analyzed by linear regression. RESULTS: The study detected reduced quality of life (QOL), with total mean of 49.7    14 and physical function grade of 61.2    22 which was significantly lower than Iran normative reported as 85.9    19. Fifty percent still suffered from moderate to severe @entity2 and Cobb angle had no statistically significant correlation with @entity2 . CONCLUSIONS: It seems that surgical treatment could not improve @entity2 related disability of @entity0 with stable thoracolumbar @entity3 at long term follow up.

title: The long-term efficacy of pedicular screw fixation at @entity0 suffering from thoracolumbar XXXX without @entity1 .

answer: @entity3


abstract: BACKGROUND: Cardiac involvement is a major cause of mortality in @entity0 with @entity6 ( @entity6 ). However, diagnosis remains underestimated and delayed, owing to subclinical @entity1 . Cardiac troponin-I measurement ( @entity7 ) on admission could improve the early diagnosis of cardiac involvement and have prognostic value. OBJECTIVES: To assess the predictive value of @entity7 in @entity0 with @entity6 for @entity2 or refractoriness. @entity0 /METHODS: The study involved a prospective cohort of adult @entity6 @entity0 with acquired severe @entity5 deficiency (<  10%) and included in the registry of the French Reference Center for @entity8 . Centralized @entity7 measurements were performed on frozen serum on admission. RESULTS: Between January 2003 and December 2011, 133 @entity0 with @entity6 (mean age, 48      17  years) had available @entity7 measurements on admission. Thirty-two @entity0 (24%) had clinical and/or electrocardiogram features. Nineteen (14.3%) had cardiac symptoms, mainly @entity4 and @entity3 . Electrocardiogram changes, mainly repolarization disorders, were present in 13 cases. An increased @entity7 level (>  0.1   g  L(-1) ) was present in 78 @entity0 (59%), of whom 46 (59%) had no clinical cardiac involvement. The main outcomes were @entity2 (25%) and refractoriness (17%). Age (P  =  0.02) and @entity7 level (P  =  0.002) showed the greatest impact on survival. A @entity7 level of >  0.25   g  L(-1) was the only independent factor in predicting @entity2 (odds ratio [OR]  2.87; 95% confidence interval [CI]  1.13-7.22; P  =  0.024) and/or refractoriness (OR  3.03; 95%  CI  1.27-7.3; P  =  0.01). CONCLUSIONS: A @entity7 level of >  0.25   g  L(-1) at presentation in @entity0 with @entity6 appears to be an independent factor associated with a three-fold increase in the risk of @entity2 or refractoriness. Therefore, @entity7 level should be considered as a prognostic indicator in @entity0 diagnosed with @entity6 .

title: Cardiac troponin-I on diagnosis predicts XXXX and refractoriness in acquired @entity6 . Experience of the French @entity8 Reference Center.

answer: @entity2


abstract: AIMS/HYPOTHESIS: The role of biomarkers of subclinical @entity2 in the early deterioration of glycaemia before @entity3 2 @entity1 is largely unknown. We hypothesised that increased levels of circulating proinflammatory biomarkers and decreased circulating @entity5 would be associated with 7  year increases of HbA1c in non- @entity1 individuals. METHODS: This study was based on individuals who participated in the prospective Cooperative Health Research in the Region of Augsburg (KORA) S4 survey (1999-2001) and the 7  year follow-up KORA F4 (2006-2008) survey. Individuals with @entity3 2 @entity1 at baseline or with a diagnosis of @entity1 in the period between both surveys were excluded, which left a sample of 850 @entity0 and @entity0 . Multivariable linear regression analyses were performed to assess associations among baseline values of leucocyte count and levels of acute-phase proteins (high-sensitivity C-reactive protein [hsCRP], @entity8 [ @entity8 ] and @entity6 ), @entity4 and @entity5 with changes in @entity7 c between baseline and follow-up. RESULTS: A high leucocyte count and high hsCRP, @entity8 and @entity4 levels were positively associated with changes in @entity7 c after adjusting for age, sex, lifestyle factors and baseline HbA1c. In contrast, the @entity5 level was inversely associated with changes in HbA1c (p value between <0.0001 and 0.020). The associations of leucocyte count and levels of hsCRP and @entity8 with HbA1c changes remained significant after additional adjustment for waist circumference and circulating lipids at baseline and for the 7  year change in waist circumference (p value between 0.004 and 0.045). CONCLUSIONS/INTERPRETATION: An elevated leucocyte count and elevated hsCRP and @entity8 were associated with early deterioration of glycaemia before the diagnosis of @entity3 2 @entity1 . These associations were largely independent of baseline abdominal adiposity and increases in waist circumference.

title: Association of subclinical @entity2 with deterioration of glycaemia before the diagnosis of XXXX 2 @entity1 : the KORA S4/F4 study.

answer: @entity3


abstract: OBJECTIVES: Despite @entity3 being the fifth highest cause of @entity2 in developed regions, there is a paucity of population-based management details for @entity0 with @entity3 . The objective of this study was to reflect on current practice and outcomes to facilitate future improvement. METHODS: A comprehensive population-based patterns-of-care study in 2 Australian states was conducted. @entity0 diagnosed with @entity3 between July 2009 and June 2011 were identified by @entity2 registries, and detailed clinical data were collected from medical records. RESULTS: Data were collected for 1863 @entity0 , 96% of those eligible. The majority resided in major cities; their median age was 72 years, and 54% were @entity0 . Over half of the cases (58%) had @entity1 at diagnosis. Resection was attempted for 20% of @entity0 but only completed in 15%. The uptake of adjuvant chemotherapy (76%) and the proportion alive at 1-year (22%) were higher than reported in previous population-based reports. Of those with no complete surgical resection, 43% received palliative chemotherapy. CONCLUSIONS: This population-based overview of the management of @entity0 with @entity3 suggests that, despite evidence that the proportion surviving and the use of adjuvant chemotherapy has increased, there may still be underutilization of @entity2 -directed therapies.

title: Describing Patterns of Care in XXXX : A Population-Based Study.

answer: @entity3


abstract: Healthcare payers make decisions on funding for treatments for diseases, such as @entity1 ( @entity1 ), on a population level, so require evidence of treatment success in appropriate populations, using usual routine care as the comparison for alternative management approaches. Such health outcomes evidence can be obtained from a number of sources. The 'gold standard' method for obtaining evidence of treatment success is usually taken as the randomized controlled prospective clinical trial. Yet the value of such studies in providing evidence for decision-makers can be questioned due to the restricted entry criteria limiting the ability to generalize to real life populations, narrow focus on individual parameters, use of placebo for comparison rather than usual therapy and unrealistic intense monitoring of @entity0 . Evidence obtained from retrospective and observational studies can supplement that from randomized clinical trials, providing that care is taken to guard against bias and confounders. However, very large numbers of @entity0 must be investigated if small differences between drugs and treatment approaches are to be detected. Administrative databases from healthcare systems provide an opportunity to obtain observational data on large numbers of @entity0 . Such databases have shown that high healthcare costs in @entity0 with @entity1 are associated with co-morbid conditions and current smoking status. Analysis of an administrative database has also shown that elderly @entity0 with @entity1 who received inhaled corticosteroids within 90 days of discharge from hospital had 24% fewer repeat hospitalizations for @entity1 and were 29% less likely to die during the 1-year follow-up period. In conclusion, there are a number of sources of meaningful evidence of the health outcomes arising from different therapeutic approaches that should be of value to healthcare payers making decisions on resource allocation.

title: Obtaining evidence for use by healthcare payers on the success of XXXX management.

answer: @entity1


abstract: BACKGROUND: Adequate expansion is critical to achieve optimal Bioresorbable Vascular Scaffolds (BVS) apposition to the vessel wall. However, compared to metallic stents, BVS present different mechanical properties. Hence, slow deployment and maintenance of @entity0 for at least 30" is recommended for BVS implantation. However, since no evidences are available demonstrating the superiority of a longer balloon dilatation time, the implantation technique is highly variable among different centers. METHODS: A total of 24 BVS-treated lesions were included in the present analysis. After BVS deployment at 12 atmosphere (ATM) the balloon was rapidly deflated and scaffold expansion was documented with an angiogram. The same balloon was then inflated again and kept at 12 ATM for 30". Finally, a further angiogram was obtained to evaluate BVS expansion. Quantitative coronary angiography (QCA) was performed at each step. RESULTS: A significant increase of @entity2 ( @entity2 )-to-reference scaffold diameter (RSD) ratio ( @entity2 to RSD Ration, MR-Ratio) from 0.70        0.10 after initial stent deployment to 0.79        0.10 after the 30"-long balloon dilation was observed (p   <   0.001). Of note, this result was consistent across all sub-segments, as well as across almost all lesion subgroups. A substantial reduction in the prevalence of @entity1 from 29  % to 17  % was registered after the 30"-long dilation. CONCLUSIONS: Our results strongly support the maintenance of @entity0 for at least 30" during BVS deployment to achieve optimal scaffold expansion and minimize the occurrence of @entity1 .

title: The duration of XXXX affects the luminal diameter of coronary segments after bioresorbable vascular scaffolds deployment.

answer: @entity0


abstract: AIM: To investigate high-intensity zone (HIZ) changes after lumbar posterior dynamic instrumentation. MATERIAL AND METHODS: Our study included 53 @entity0 : 27 @entity0 in group 1, 26 @entity0 in group 2. All @entity0 had one or two levels of @entity2 with an HIZ confirmed by magnetic resonance imaging (MRI). Group 1 underwent one- or two-level dynamic lumbar posterior instrumentation. Group 2 was treated conservatively with an exercise program. @entity0 were evaluated using MRI, a numerical visual analog @entity1 scale (VAS), and the @entity3 Index (ODI) at baseline, at 1 year after surgery, and at final follow-up evaluation. RESULTS: The mean duration of follow-up was 49.3 months in group 1 and 47.19 months in group 2. The baseline VAS and ODI scores were similar for both groups. The mean VAS score of group 1 was significantly improved at 1 year after surgery and at final follow-up. The mean ODI value was lower in group 1 than in group 2 at 1 year and at final follow-up. Pfirrmann grades in group 1 significantly differed at 1 year and at final follow-up but did not change in group 2. The number of HIZs significantly decreased in from baseline to 1 year and from baseline to final follow-up in group 1 but did not differ in group 2. CONCLUSION: Dynamic lumbar stabilization systems are promising. Observations such as Pfirrmann grade improvements and disappearance of HIZs are concordant with improvements in VAS and ODI scores demonstrate that dynamic stabilization systems may provide an environment for regeneration.

title: Effect of Posterior Dynamic Instrumentation on High-Intensity Zone in Lumbar XXXX .

answer: @entity2


abstract: BACKGROUND: Among the various diagnostic criteria for @entity3 , the ratio criteria have been controversial. However, the amended insulin- @entity1 ratio exhibited excellent diagnostic performance in a recent retrospective cohort study, although it has not yet been validated in other @entity0 cohorts. We examined the diagnostic performance of the current criteria of the Endocrine Society, insulin- @entity1 ratio, C-peptide- @entity1 ratio, and amended ratios in terms of differentiating @entity3 . METHODS: We reviewed the medical records of @entity0 who underwent evaluation for @entity2 from 2000 to 2013. Fourteen @entity0 with histopathologically confirmed @entity3 and 18 @entity0 without clinical evidence of @entity3 were included. The results of a prolonged fast test were analyzed according to the abovementioned criteria. RESULTS: Fulfilling all three Endocrine Society criteria-plasma levels of @entity1 (<3.0 mmol/L), insulin (>= 18 pmol/L), and C-peptide (>= 0.2 nmol/L)-exhibited 100% sensitivity and 89% specificity. Fulfilling the @entity1 and C-peptide criteria showed 100% sensitivity and 83% specificity, while fulfilling the @entity1 and insulin criteria showed 100% sensitivity and 72% specificity. Among the ratio criteria, the insulin- @entity1 ratio [>24.0 (pmol/L)/(mmol/L)] gave the highest area under the receiver operating characteristic curve, with 93% sensitivity and 94% specificity. CONCLUSION: Fulfilling the @entity1 , insulin, and C-peptide criteria of the Endocrine Society guidelines exhibited the best diagnostic performance for @entity3 . Nonetheless, the insulin- @entity1 ratio may still have a role in the biochemical diagnosis of @entity3 .

title: Clinical Implications of Various Criteria for the Biochemical Diagnosis of XXXX .

answer: @entity3


abstract: Computed tomographic (CT) studies of 80 @entity1 with chronic @entity5 (nasal @entity0 (n = 19), @entity3 (n = 46), nonspecific @entity4 (n = 11), and @entity4 (n = 4)) were reviewed retrospectively by two independent observers. Each observer filled out a custom-designed list to record his or her interpretation of the CT signs and selected a diagnosis. Accuracy, sensitivity, specificity, positive predictive value ( @entity2 ), and negative predictive value (NPV) were calculated for the diagnosis of each disease. The agreement between observers was evaluated. The CT signs corresponded to those previously described in the literature. CT had an accuracy greater than 90% for each observer in all disease processes. The sensitivity, specificity, @entity2 , and NPV were greater than 80% in all @entity1 with the exception of the @entity2 of @entity4 (80% for observer A and 44% for observer B). There was a substantial, to almost perfect, agreement between the two observers regarding the CT signs and diagnosis. This study indicates a high accuracy of CT for diagnosis of @entity1 with chronic @entity5 . The differentiation between @entity3 restricted to the nasal passages and @entity4 may be difficult when the foreign body is not visible.

title: Diagnostic value of computed tomography in XXXX with chronic @entity5 .

answer: @entity1


abstract: UNASSIGNED: The present study was undertaken to characterize the genetic variation present in lymphoxin A gene (LTA gene) encoding for the lymphotoxin A protein also known as @entity0 @entity1 factor beta, a cytokine produced by lymphocytes, known to be cytotoxic for a wide range of @entity0 cells both in vitro and in vivo, and, which is essential for normal immunological development; in 40 animals of 5 diverse @entity3 Indian @entity3 breeds. These breeds survive under the harsh and tough tropical climatic conditions of various parts of the Indian subcontinent. The LTA gene in the present study was observed to contain 33 SNPs and 3 small insertion/deletion polymorphisms. Four SNPs occurred in the coding regions of the gene viz. @entity4 and @entity5 in exon 2 and @entity6 and @entity7 in exon 3, of which the SNP @entity4 in exon 2 resulted in a non-synonymous @entity2 change @entity8 . This @entity2 change was however predicted not be affecting the protein function in any manner. The gene contained putative transcription factor binding sites for the c-Re1 and for Pax-4 transcription factors. A putative promoter region was also predicted on the reverse DNA strand from position 894 to 644. Several repeat elements and microsatellite repeats were detected to be occurring across the 3.2kb LTA gene sequence. The study showed the occurrence of 40 genotypes and 48 most probable haplotypes. The genotypes at the observed SNP positions in the LTA gene were in near Hardy-Weinberg equilibrium. A negative Tajima's D value that was not significant statistically at P>0.10 indicated that the neutral mutation hypothesis could not be excluded. The genetic variations observed in the LTA gene in the present study have not been reported earlier and these could possibly be used as molecular markers for further studies involving association of the gene variability with disease resistance/tolerance traits.

title: Nucleotide polymorphisms in the bovine lymphotoxin A gene and their distribution among @entity3 XXXX breeds.

answer: @entity3


abstract: OBJECTIVES: This study was designed to evaluate the efficacy and safety of reducing @entity1 ( @entity5 ) dosing frequency from daily to every other day (EOD) or twice a week (TW) according to clinical response in @entity4 with @entity0 ( @entity0 ) and treated with @entity5 . METHODS: One hundred and ninety-one @entity4 with @entity0 were given 7 mg/kg @entity5 daily for at least 4 weeks. Depending on clinical response, the dosing frequency was tapered from daily to EOD over the next 4 weeks and further to TW for an additional 4 weeks. Safety was evaluated through physical examinations, clinical pathology and the monitoring of adverse events (AEs). RESULTS: The majority of @entity4 were able to have their dose of @entity5 tapered to either EOD (15.5%) or TW (62.9%) according to the clinical response. Observed AEs were most frequently mild and self-limiting @entity3 and @entity2 . A higher percentage of AEs occurred with daily administration (73%) compared with other dosing regimens (27%). CONCLUSIONS AND RELEVANCE: Following 4 weeks of daily dosing at 7 mg/kg, @entity5 may be tapered to EOD or TW while maintaining the desired therapeutic response in @entity4 with @entity0 . Additionally, @entity5 appears to be well tolerated with fewer AEs at EOD or TW dosing. Establishing the lowest effective dosing frequency of @entity5 improves the drug's safety profile.

title: Clinical efficacy and safety following dose tapering of @entity1 in @entity4 with XXXX .

answer: @entity0


abstract: UNASSIGNED: Over the last 5 years there has been a surge in interest in the molecular classification of @entity2 . The effect of molecular subtyping on current treatment decisions is limited to avoidance of adjuvant @entity5 chemotherapy in stage II microsatellite unstable-high disease and avoidance of @entity3 -targeted antibodies in extended RAS mutant @entity1 . The emergence of specific novel combination therapy for the @entity4 -mutant cohort and of the microsatellite unstable-high cohort as a responsive group to immune checkpoint inhibition shows the growing importance of a clinically relevant molecular taxonomy. Clinical trials such as the Medical Research Council FOCUS4 trial using biomarkers to select @entity0 for specific therapies are currently open and testing such approaches. The integration of mutation, gene expression and pathological analyses is refining our understanding of the biological subtypes within @entity2 . Sharing of data sets of parallel sequencing and gene expression of thousands of @entity1 among independent groups has allowed the description of disease subsets and the need for a validated consensus classification has become apparent. This biological understanding of the disease is a key step forward in developing a stratified approach to @entity0 management. The discovery of stratifiers that predict a response to existing and emerging therapies will enable better use of these treatments. Improved scientific understanding of the biological characteristics of poorly responsive subgroups will facilitate the design of novel biologically rational combinations. Novel treatment regimens, including the combination of new drugs with radiation, and the discovery and validation of their associated predictive biomarkers will gradually lead to improved outcomes from therapy.

title: Molecular Taxonomy and Tumourigenesis of XXXX .

answer: @entity2


abstract: BACKGROUND: To evaluate the respective or combinatory efficacy of locally delivered 2% @entity1 (MO), and scaling and root planning (SRP) by assessing both clinical parameters and the loads of four main periodontal pathogens in treating @entity6 ( @entity6 ). METHODS: Seventy adults with @entity6 were randomly assigned to the three treatment groups: 1) SRP alone; 2) MO alone; and 3) combinatory use of SRP and MO (SRP + MO). Before and 7 days after the treatments, we evaluated both clinical parameters ( @entity5 [ @entity5 ] and sulcus bleeding index [SBI]) and the gene load of four main periodontal pathogens ( @entity4 [Aa], @entity7 [Fn], @entity2 [Pg], and @entity3 [Pi]). RESULTS: The bacterial prevalence per @entity0 was: Aa, 31.25%; Fn, 100%; Pg, 95.31%; and Pi, 98.44%. Seven days after treatment, the three treatments significantly reduced both @entity5 and SBI, but not detection frequencies of the four pathogens. For @entity5 , the reduction efficacy of SRP + MO was significantly higher than that of either MO or SRP. Only Pg responded significantly to SRP. Pg and Fn were significantly reduced in the presence of MO. Only SRP + MO showed a significant reduction effect on the gene load of Pi. The reduction of @entity5 significantly correlated with the gene load of Pi (r=0.26; P=0.042) but not of the other bacteria. CONCLUSION: SRP and MO reduced the load of Pi in an interdependent pattern, which correlated with symptomatic improvements of @entity6 .

title: Scaling and root planning, and locally delivered @entity1 reduces the load of XXXX in an interdependent pattern, correlating with symptomatic improvements of @entity6 : a short-term randomized clinical trial.

answer: @entity3


abstract: BACKGROUND: Food hypersensitivity is characterized by a wide range of symptoms. The relationship between symptoms and food is more frequently suspected than objectively proven. Basophil activation test (BAT) is based on the evaluation of activation markers on blood basophils in vitro stimulated with drugs or allergens. The aim of the study was to evaluate the usefulness of BAT when introduced in the routine work-up of suspected @entity1 . METHODS: BAT was requested in subjects with food adverse reactions when a discrepancy existed among history and skin prick test (SPT) and/or specific IgE. Data from 150 subjects were analysed using @entity3 as basophil activation marker. Thirty controls were evaluated for cut-offs. Immunoblots was performed with the sera of representative subjects positive for BAT and negative for SPT and sIgE. RESULTS: 1,024 BAT were carried out, the agreement (positive/positive and negative/negative) was 78.5% for BAT vs. SPT and 78.3% for BAT vs. IgE. @entity2 @entity0 , but not @entity2 controls, more frequently had a positive BAT than non- @entity2 @entity0 (P   <   0.0001). Among subjects with positive BAT, those with negative sIgE had lower total IgE, P   =   0.001. Nearly 23.3% of all subjects had positive BAT (for at least one tested food) and both negative sIgE and SPT. Immunoblots revealed the presence of sIgE for the tested foods in representative @entity0 with positive BAT, negative SPT and sIgE. CONCLUSION: Introduction of BAT in routine of @entity1 , limited to subjects with a discrepancy between history and traditional tests, might be useful particularly when total IgE are low.    2015 International Clinical Cytometry Society.

title: Evaluation of basophil activation test in suspected XXXX .

answer: @entity1


abstract: BACKGROUND: @entity8 ( @entity8 ) complicates at least 20  % of large hemispheric @entity6 (LHI) and may result in @entity2 or @entity4 . @entity5 ( @entity5 ) is a standard but crude measure of @entity1 severity. We propose that volumetric analysis of shifts in cerebrospinal fluid (CSF) over time provides a reliable means of quantifying the spectrum of @entity1 severity after LHI. METHODS: We identified 38 @entity0 from 2008 to 2014 with NIHSS >= 8, baseline CT <6  h after @entity3 onset, at least 1 follow-up (FU) CT, and no parenchymal @entity7 . The volumes of CSF (sulci, ventricles, and cisterns) ipsilateral (IL) and contralateral (CL) to @entity6 on baseline and FU CTs were quantified by manually assisted outlining with MIPAV image analysis software, as was @entity6 volume and @entity5 on FU CTs. Percentage change in CSF volumes (   CSF) from baseline to FU scans was correlated with @entity5 and compared in those with vs. without @entity1 (defined as hemicraniectomy, osmotic therapy, or @entity2 with @entity5 >= 5  mm). RESULTS: 11 of 38 subjects (29  %) developed @entity1 . Neither baseline NIHSS nor CSF volume differed between those with and without @entity1 (median NIHSS 18 vs. 13, p  =  0.12, CSF volume 102 vs. 124  ml, p  =  0.16). Inter-rater reliability for CSF measurements was excellent (intraclass correlation coefficient 0.97).    CSF correlated strongly with @entity5 at peak @entity1 (r  =  -0.75), even adjusting for @entity6 volume (p  =  0.009).    CSF was also greater in those with @entity1 [-55  % (IQR -49 to -62) vs. -36  % (-27 to -45), p  =  0.004].    CSF was the greatest within IL sulci [-97  % (-86 to -99) vs. -71  % (-41 to -79), p  =  0.002] but also significantly greater within CL sulci in those with @entity1 [-50  % (-29 to -65) vs. -25  % (0 to -31), p  =  0.014]. More than half this CSF volume reduction occurred by the time of first FU CT around 24  h after @entity3 , while @entity5 rose later. CONCLUSIONS: Volumetric CSF analysis reliably quantifies @entity8 and distinguishes those with @entity1 and @entity5 from those with a more benign course after LHI.    CSF may provide an earlier and more sensitive indicator of @entity1 severity across a broader dynamic range than @entity5 .

title: CSF Volumetric Analysis for Quantification of @entity8 After XXXX .

answer: @entity6


abstract: PURPOSE: To demonstrate the possibility and quantify the impact of operating a clinical CT scanner at exceptionally high x- @entity2 tube voltage for better penetration through metal objects and facilitating metal artifact reduction. METHODS: We categorize metal objects according to the data corruption severeness (level of distortion and complete photon starvation fraction). To demonstrate feasibility and investigate the impact of high voltage scanning we modified a commercial GE LightSpeed VCT scanner (generator and software) to enable CT scans with x- @entity2 tube voltages as high as 175 kVp. A 20 cm diameter water phantom with two metal rods (10 mm stainless and 25 mm @entity1 ) and a water phantom with realistic metal object (spine cage) were used to evaluate the data corruption and image artifacts in the absence of any algorithm correction. We also performed simulations to confirm our understanding of the transmitted photon levels through metal objects with different size and composition. RESULTS: The reconstructed images at 175 kVp still have significant dark shading artifacts, as expected since no special scatter correction or beam hardening was performed but show substantially lower noise and photon starvation than at lower kVp due to better beam penetration. Analysis of the raw data shows that the photon starved data is reduced from over 4% at 140 kVp to below 0.2% at 175 kVp. The simulations indicate that for clinically relevant @entity1 and stainless objects a 175 kVp tube voltage effectively avoids photon starvation. CONCLUSION: The use of exceptionally high tube voltage on a clinical CT system is a practical and effective solution to avoid photon starvation caused by certain metal implants. Sparse and hybrid high-voltage protocols are being considered to maintain low @entity0 dose. This opens the door to algorithmic physics-based corrections rather than treating the data as missing and relying on missing data algorithms. Some of the authors are employees of General Electric.

title: MO-FG-CAMPUS-IeP2-05: Feasibility Demonstration of High-Voltage Clinical CT and Impact On X- XXXX Penetration Through Metal Objects.

answer: @entity2


abstract: UNASSIGNED: @entity4 ( @entity4 ) has increasingly been recognized, and it is well known that @entity4 is sometimes complicated by @entity5 ( @entity3 ). In this study, 55 cases of @entity4 with @entity3 were retrospectively analyzed, focusing on therapeutic strategies and outcomes. Of 169 @entity4 cases (75 males, 84 females), 55 (36 males, 19 females) were complicated by @entity3 . @entity4 was diagnosed based on clinical symptoms, neuroimaging, and/or low cerebrospinal fluid pressure. Presence of @entity1 and diffuse meningeal enhancement on magnetic resonance imaging were regarded as the most important criteria. Among 55 @entity4 with @entity3 cases, 13 improved with conservative treatment, 25 initially received an epidural blood patch (EBP), and 17 initially underwent irrigation of the @entity2 . Of the 25 initially treated with EBP, 7 (28.0%) needed @entity3 surgery and 18 (72.0%) recovered fully without surgery. Of 17 @entity3 cases initially treated with surgery, 6 (35.7%) required no EBP therapy and the other 11 (64.3%) needed EBP and/or additional @entity3 operations. In the latter group, 2 cases had transient severe complications during and after the procedures. One of these 2 cases developed a @entity6 . Despite this single, non-severe complication, all enrolled in this study achieved good outcomes. The present study suggests that @entity0 initially receiving @entity3 surgery may need additional treatments and may occasionally have complications. If conservative treatment is insufficient, EBP should be performed prior to @entity2 irrigation.

title: XXXX Associated with @entity4 : Therapeutic Strategies and Outcomes of 55 Cases.

answer: @entity5


abstract: BACKGROUND _ AIMS: Although approximately 50% of @entity6 @entity2 @entity0 are surgically cured, it is currently not possible to distinguish these @entity0 from those at high risk of recurrence. The recent advent of routine adjuvant chemotherapy for these @entity0 has greatly complicated the identification of new markers predicting the response to surgery, which is now reliant on archived materials. Microarray analysis allows fine @entity1 classification but cannot be used with @entity4 -embedded archival samples. METHODS: We used microarray analysis of a unique set of fresh-frozen @entity1 samples from @entity6 @entity0 who had surgery as the only form of treatment to identify molecular signatures that characterize @entity1 from @entity0 with good and bad prognosis. RESULTS: Unsupervised hierarchical clustering and a K-nearest neighbors-based classifier identified groups of @entity0 with significantly different survival (P = .019 and P = .0001). Expression profiling outperformed previously reported genetic markers of prognosis such as @entity3 and @entity5 mutational status and allelic imbalance in chromosome 18q, which were of limited prognostic power in this study. Functional categories significantly enriched in gene-expression differences included protein transport and folding. The prognostic potential of the RAS homologue @entity7 , one of the most differentially expressed genes, was further investigated using immunohistochemistry and a tissue microarray containing 137 independent @entity1 samples. Reduced @entity7 expression was associated with significantly shorter survival (P = .01). CONCLUSIONS: This study shows that gene-expression profiling of surgical @entity1 samples can predict recurrence in @entity6 @entity0 . Therefore, this approach could be used to guide decisions concerning the clinical management of these @entity0 .

title: Gene-expression profiling predicts recurrence in @entity6 XXXX .

answer: @entity2


abstract: UNASSIGNED: Tissue engineering benefits from novel materials with precisely tunable physical, chemical and mechanical properties over a broad range. Here we report a practical approach to prepare @entity2 silk fibroin hydrogels using the principle of @entity1 ( @entity1 ). A combination of reconstituted silk fibroin (RSF) and @entity0 (non-solvent), with a final concentration of 2.5% w/v and 12.5% v/v respectively, maintained at 22   C temperature turned into a hydrogel within 10 hours. Freeze-drying of this gel gave a foam with a porosity of 88%, a water uptake capacity of 89% and a swelling index of 8.6. The gelation kinetics and the loss tangent of the gels were investigated by rheometry. The changes in the morphology of the porous foams were visualized by SEM. The changes in RSF chemical composition and the relative fraction of its secondary structural elements were analyzed by ATR-FTIR along with Fourier self-deconvolution. And, the changes in the glass transition temperature, specific heat capacity and the relative fraction of crystallinity of RSF were determined by TM-DSC. Data suggested that RSF-water- @entity0 behaved as a polymer-solvent-non-solvent ternary phase system, wherein the demixing of the water- @entity0 phases altered the thermodynamic equilibrium of RSF-water phases and resulted in the desolvation and eventual separation of the RSF phase. Systematic analysis revealed that both gelation time and the properties of hydrogels and porous foams could be controlled by the ratios of RSF and non-solvent concentration as well as by the type of non-solvent and incubation temperature. Due to the unique properties we envisage that the herein prepared @entity1 induced RSF hydrogels and porous foams can possibly be used for the encapsulation of cells and/or for the controlled release of both hydrophilic and hydrophobic drugs.

title: Silk fibroin gelation via XXXX .

answer: @entity1


abstract: OBJECTIVES: The aim of the present study was to assess the outcome of @entity0 with @entity2 ( @entity2 ) complicated by @entity4 ( @entity4 ) receiving drug-eluting stents (DES) compared with bare-metal stents (BMS). Data comparing these two stent technologies in @entity2 with @entity4 were limited. METHODS: A total of 783 @entity0 with @entity2 and @entity4 undergoing early revascularisation were included in the randomised Intra-aortic Balloon Pump in Cardiogenic Shock II trial (n=600) and the associated registry (n=183). @entity0 receiving no stent or both, DES and BMS, were excluded. Primary end point was the composite of 1-year mortality or re- @entity2 . RESULTS: Of the total cohort, 652 (83%) @entity0 received either solely DES or BMS and were included in the present analysis. Of these, 276 (42%) @entity0 received DES and 376 (58%) received BMS. After adjustment for baseline characteristics, there was no significant difference between DES and BMS regarding the primary end point (HR 0.83 (CI 0.64 to 1.06); p=0.14). There was an independent association of BMS use with older age, @entity3 and @entity1 . DES use was associated with prior known dyslipidaemia, baseline haemoglobin level, anterior @entity2 and treatment at frequently enrolling centres. CONCLUSIONS: Despite the frequent use of DES nowadays, a substantial number of @entity0 were treated by BMS in @entity2 complicated by @entity4 . After adjustment for risk factors, the 1-year outcome of @entity0 treated by DES compared with BMS was similar. TRIAL REGISTRATIONNUMBER: www.clinicaltrials.gov: NCT00491036.

title: Drug-eluting stents versus bare-metal stents in @entity2 with XXXX .

answer: @entity4


abstract: OBJECTIVE: The aim of the study was to investigate the role of single-nucleotide polymorphisms (SNPs) located in the @entity4 ( @entity4 ) gene in treatment response to antivascular endothelial growth factor ( @entity1 ) therapy for neovascular age-related @entity3 (nvAMD). METHODS: Four SNPs in the @entity4 gene ( @entity5 , @entity6 , @entity7 , and @entity8 ) were genotyped in a study cohort of 377 nvAMD @entity0 who received the loading dose of three monthly ranibizumab injections. Treatment response was assessed as the change in visual acuity after three monthly loading injections compared with baseline. RESULTS: SNP @entity7 was associated with change in visual acuity after 3 months of treatment. @entity0 carrying the GA or AA genotypes performed significantly worse than individuals carrying the GG genotype (P=0.01). A cumulative effect of @entity7 in the @entity4 gene and @entity9 located in the @entity1 receptor 2 ( @entity2 or @entity2 ) gene, previously associated with treatment response, was observed. @entity0 carrying two risk alleles performed significantly worse than @entity0 carrying zero or one risk allele (P=0.03), and @entity0 with more than two risk alleles responded even worse to the therapy (P=3*10). The combined effect of these two SNPs on the response was also seen after 6 and 12 months of treatment. CONCLUSION: This study suggests that genetic variation in @entity4 , a key molecule in @entity1 -driven neovascularization, influences treatment response to ranibizumab in nvAMD @entity0 . The results of this study may be used to generate prediction models for treatment response, which in the future may help tailor medical care to individual needs.

title: A genetic variant in @entity4 is associated with worse response to ranibizumab treatment in neovascular age-related XXXX .

answer: @entity3


abstract: BACKGROUND: @entity3 is the leading cause of @entity2 in @entity1 . UK national guidelines have recommended that all @entity0 with severe @entity3 (SHI) should be treated in neuroscience centers. The aim of this study was to investigate the effect of specialist neuroscience care on mortality after SHI. METHODS: We conducted a cohort study using prospectively recorded data from the largest European @entity1 registry, for adult @entity0 presenting with @entity1 between 2003 and 2009. Mortality and unadjusted odds of @entity2 were compared for @entity0 with SHI treated in neuroscience units (NSU) versus nonspecialist centers. To control for confounding, odds of @entity2 associated with non-NSU care were calculated using propensity score-adjusted multivariate logistic regression (explanatory covariates: age, Glasgow @entity4 Score, Injury Severity Score, treatment center). Sensitivity analyses were performed to study possible bias arising from selective enrollment, from loss to follow-up, and from hidden confounders. RESULTS: 5411 @entity0 were identified with SHI between 2003 and 2009, with 1485 (27.4%) receiving treatment entirely in non-NSU centers. SHI management in a non-NSU was associated with a 11% increase in crude mortality (P<0.001) and 1.72-fold (95% confidence interval: 1.52-1.96) increase in odds of @entity2 . The case mix adjusted odds of @entity2 for @entity0 treated in a non-NSU unit with SHI was 1.85 (95% confidence interval: 1.57-2.19). These results were not significantly changed in sensitivity analyses examining selective enrollment or loss to follow-up, and were robust to potential bias from unmeasured confounders. CONCLUSIONS: Our data support current national guidelines and suggest that increasing transfer rates to NSUs represents an important strategy in improving outcomes in @entity0 with SHI.

title: The effect of specialist neurosciences care on outcome in adult severe XXXX : a cohort study.

answer: @entity3


abstract: After @entity0 /reperfusion (I/R) injury, monocytes home to the kidney and differentiate into activated macrophages. Whereas proinflammatory macrophages contribute to the @entity0 , an alternatively activated phenotype can promote normal renal repair. The microenvironment of the kidney during the repair phase mediates the transition of macrophage activation from a proinflammatory to a reparative phenotype. In this study, we show that macrophages isolated from @entity1 kidneys during the tubular repair phase after I/R exhibit an alternative activation gene profile that differs from the canonical alternative activation induced by @entity2 -stimulated @entity5 signaling. This unique activation profile can be reproduced in vitro by stimulation of bone marrow-derived macrophages with conditioned media from serum-starved @entity1 proximal tubule cells. Secreted tubular factors were found to activate macrophage @entity6 and @entity7 but not @entity5 , leading to induction of the unique alternative activation pattern. Using @entity6 -deficient bone marrow-derived macrophages and pharmacologic inhibition of @entity7 , we found that tubular cell-mediated macrophage alternative activation is regulated by @entity7 activation. Both in vitro and after renal I/R, tubular cells expressed @entity4 , a known @entity7 activator, and this pathway was required for in vitro alternative activation of macrophages by tubular cells. Furthermore, administration of a neutralizing antibody against @entity4 after renal I/R attenuated kidney macrophage alternative activation and suppressed tubular proliferation. Taken together, these data show that tubular cells can instruct macrophage activation by secreting @entity4 , leading to a unique macrophage reparative phenotype that supports tubular proliferation after @entity3 .

title: @entity4 Promotes Macrophage Alternative Activation after XXXX /Reperfusion Injury.

answer: @entity0


abstract: BACKGROUND: Endovascular intervention using a stent is a mainstream treatment for @entity1 . To assess the effect of intervention strategies on @entity2 hemodynamics, we have developed a fast virtual stenting (FVS) technique to simulate stent deployment in @entity0 -specific @entity2 . However, quantitative validation of the FVS against experimental data has not been fully addressed. In this study, we performed in vitro analysis of a @entity0 -specific model to illustrate the realism and usability of this novel FVS technique. METHODS: We selected a @entity0 -specific @entity2 and reproduced it in a manufactured realistic aneurismal phantom. Three numerical simulation models of the @entity2 with an Enterprise stent were constructed. Three models were constructed to obtain the stented @entity2 : a physical phantom scanned by micro-CT, fast virtual stenting technique and finite element method. The flow in the three models was simulated using a computational fluid dynamics software package, and the hemodynamics parameters for the three models were calculated and analyzed. RESULTS: The computational hemodynamics in the @entity0 -specific @entity2 of the three models resembled the very well. A qualitative comparison revealed high similarity in the wall shear stress, streamline, and velocity plane among the three different methods. Quantitative comparisons revealed that the difference ratios of the hemodynamic parameters were less than 10%, with the difference ratios for area average of wall shear stress in the @entity2 being very low. CONCLUSIONS: In conclusion, the results of the computational hemodynamics indicate that FVS is suitable for evaluation of the hemodynamic factors that affect treatment outcomes.

title: Phantom-based experimental validation of fast virtual deployment of self-expandable stents for XXXX .

answer: @entity1


abstract: STUDY DESIGN: Prospective cohort with concurrent controls. OBJECTIVE: To establish accuracy, reliability, and validity of the Vitronic 3D Body Scanner for the evaluation of torso asymmetry in @entity0 with @entity2 . SUMMARY OF BACKGROUND DATA: Improved appearance is an important expectation of treatment for @entity0 with @entity1 and their parents. Despite being the "gold standard" for quantifying outcomes, Cobb angles do not explain perception of appearance or quality of life. Surface topography is an attractive noninvasive alternative to radiography but has not been studied in the context of @entity0 -centered outcomes. METHODS: Thirty-six adolescents with @entity2 undergoing surgical correction had pre- and postoperative radiographs and evaluation of standing posture, torso surface shape, and responses to the Scoliosis Research Society-22 and Spinal Appearance Questionnaire. Twenty-one adolescents without @entity1 were evaluated for comparison. Scanner accuracy was assessed by scanning an object of known dimensions. Within-session reliability of body shape measures constructed from scan data was assessed. Discriminant validity was assessed by examining pre- to postoperative differences. Concurrent validity was examined through correlations of scan measures with radiographs, optoelectronic measures of posture, and self-report responses to the Scoliosis Research Society-22 and Spinal Appearance Questionnaire. RESULTS: Scan system measurement error was 1.74    1.56 mm. Within-session reliability was excellent for the control (intraclass correlation coefficient = 0.83) and @entity1 (intraclass correlation coefficient = 0.94) groups. Medial/lateral torso shift, rotation, and right/left asymmetry differed significantly among the preoperative, postoperative, and control groups (analysis of variance, P < 0.05). Torso asymmetry measures correlated with radiographical measures (r = 0.43-0.51), optoelectronical measures of posture and symmetry (r = 0.33-0.75), and appearance and quality-of-life domains of the Scoliosis Research Society-22 (r = 0.35-0.64) and the Spinal Appearance Questionnaire (r = 0.48-0.67). CONCLUSION: The Vitronic 3D Body Scanner has sufficient accuracy, reliability, and validity to monitor torso asymmetry due to @entity1 . Scan-based measures differentiate between normal and pathological and between preoperative and postoperative body shape and show good correlation with measures of appearance and quality of life.

title: Accuracy, reliability, and validity of a 3-dimensional scanner for assessing torso shape in XXXX .

answer: @entity2


abstract: BACKGROUND: Nystagmus in @entity0 with @entity1 ( @entity1 ) is generally attributed to @entity2 . Lesions in other regions may result in @entity3 . The identification of these other sites is enhanced by using 3-Tesla magnetic resonance imaging (3TMRI) due to increased signal-to-noise ratio. OBJECTIVE: We sought to evaluate the distribution of structural lesions and disruption of tracts in @entity0 with @entity3 secondary to @entity1 using 3TMRI. METHODS: Twenty-four @entity0 (20 @entity0 , 4 @entity0 ; age range 26-55  years) with @entity3 secondary to @entity1 underwent 3TMRI brain scans; and 18 @entity0 had diffusion tensor imaging (DTI) for tractography. RESULTS: Nystagmus was bidirectional in 11, right-sided in 6 and left-sided in 7. We identified 194 lesions in 20 regions within the neural integrator circuit in 24 @entity0 ; 140 were within the cortex and 54 were within the brainstem. Only two @entity0 had no lesions in the cortex, and 9 had no lesions in the brainstem. There was no relationship between side of lesion and direction of @entity3 . Thirteen of 18 (72  %) had tract disruption with fractional anisotropy (FA) values below 0.2. FA was significantly lower in bidirectional compared to unidirectional @entity3 (p  =  0.006). CONCLUSION: In @entity1 @entity0 with @entity3 , lesions in all cortical eye fields and their descending connections were evident. Technical improvements in tractography may help identify the specific site(s) resulting in @entity3 in @entity1 .

title: @entity3 and XXXX using 3-Tesla magnetic resonance imaging.

answer: @entity1


abstract: INTRODUCTION: Data about the expression of Epidermal Growth Factor Receptors (EGFRs) in @entity9 remain scarce. RESULTS: 101 @entity0 were enrolled including 53 controls. All @entity6 (n = 38) and @entity2 (n = 5) were @entity5 positive. @entity7 ( @entity7 ) (n = 8) and control colons (n = 53) were @entity5 negative in half of cases (p < 0.0001). A well significant gradient of increased @entity5 expression was observed between adjacent mucosa, @entity3 , @entity4 ( @entity4 ) (n = 30), @entity8 ( @entity8 ) @entity6 (n = 9) and @entity1 (p < 0.0001). @entity5 overexpression was reported in 100% of @entity1 , 77.8% of @entity8 , and 10% of @entity4 @entity6 . By multivariate analysis in @entity6 , associated factors with @entity5 overexpression were @entity8 and tubulo-villous feature. MATERIALS AND METHODS: All @entity0 undergoing colonoscopy in the university center of Saint-Etienne were eligible to the study from December 2015 to March 2016. In @entity0 with @entity2 (lesions group), biopsies were performed on the lesion before its resection, and on the adjacent and distal colon mucosa. In control group, biopsies were performed in the right and left side colon. The @entity5 expression was assessed by immunohistochemical scores (Goldstein grade, intensity of staining, composite score), using a primary mouse monoclonal antibody ( @entity5 , clone 113, Novocastra). Outcomes were compared using Kruskal-Wallis and/or Mann-Whitney-U tests, appropriately. The associated clinical, endoscopic and histological factors with @entity5 overexpression (composite score >=  6) were assessed for @entity6 by logistic regression. CONCLUSIONS: @entity5 are early involved in @entity2 , and their expression is strongly correlated to the @entity1 stage, leading to validate @entity5 as an interesting surface biomarker of @entity6 .

title: The level of epidermal growth factor receptors expression is correlated with the advancement of XXXX : validation of a surface biomarker.

answer: @entity9


abstract: The rising incidence of @entity3 , @entity9 ( @entity9 ) and @entity8 ( @entity8 ) has signalled a need to increase awareness, treatment and control of @entity5 . There continues to be a need for effective antihypertensive medications since @entity5 is a major precursor to various forms of @entity4 . The renin-angiotensin (AT) @entity11 system (RAAS) is a key component to the development of @entity5 and can be one target of drug therapy. Angotensin II (ATII) receptor blockers (ARBs) are the most recent class of agents available to treat @entity5 , which work by by inhibiting ATII at the receptor level. Currently, national consensus guidelines recommend that ARBs should be reserved for @entity5 @entity0 who cannot tolerate @entity10 ( @entity10 ) inhibitors (ACEIs). ARBs, however, are moving to the forefront of therapy with a promising role in the area of renoprotection and @entity9 . Recent trials such as the The Renoprotective Effect of the @entity15 -Receptor Antagonist @entity14 in @entity0 with @entity2 Due to @entity12 Trial (IDNT), the Effect of @entity14 on the Development of @entity13 in @entity0 with @entity12 (IRMA2), and The Effects of @entity16 on Renal and Cardiovascular Outcomes in @entity0 with @entity12 and @entity2 (RENAAL) study have demonstrated the renoprotective effects of ARBs in @entity0 with @entity7 2 @entity1 . The Valsartan Heart Failure Trial (Val-HeFT) adds to the growing body of evidence that ARBs may improve morbidity and mortality in @entity9 @entity0 . As a class, ARBs are well tolerated and have a lower incidence of cough and @entity6 compared to ACEIs. This article reviews the differences among the ARBs, existing efficacy data in @entity5 , and explores the role of ARBs in @entity9 and @entity2 .

title: Angiotensin II receptor blockers for the treatment of XXXX .

answer: @entity5


abstract: There is only limited morphologic information on long-term alterations and neurotransmitter changes after perinatal @entity12 , and no long-term study showing @entity2 has been reported so far. We used an animal model for perinatal @entity12 well documented in the @entity0 to investigate the @entity7 as a species highly mature at birth. Cesarean section was performed on full-term pregnant @entity7 , and pups, still in membranes, were placed into a water bath at 37 degrees C for @entity12 periods from 2 to 4 min. Thereafter pups were given to surrogate mothers and examined at 3 mo of age. We studied brain areas reported to be @entity3 -sensitive. @entity2 was evaluated by fluoro-jade, @entity4 by Nissl, reactive @entity14 by glial fibrillary acidic protein staining, and differentiation by neuroendocrine-specific protein C immunoreactivity. We tested @entity6 hydroxylase, the vesicular @entity10 transporter, and @entity9 beta-hydroxylase, representing the monoaminergic system; the vesicular @entity8 transporter; and the excitatory @entity5 carrier 1. @entity2 was evident in cerebellum, hippocampal area @entity15 , and @entity13 , and @entity4 could be observed in cerebellum and @entity13 ; @entity14 was observed in cerebellum, hippocampus, @entity13 , and parietal cortex; dedifferentiation was found in @entity13 and striatum; and monoaminergic, cholinergic, and @entity11 acidergic deficits were shown in several brain regions. The major finding of the present study was that @entity2 and dedifferentiation evolved in the @entity7 , a species highly mature at birth. The relevance of this contribution is that a simple animal model of perinatal @entity12 resembling the clinical situation of intrauterine @entity3 - @entity1 and presenting with @entity2 was characterized.

title: Neurodegeneration, neuronal loss, and neurotransmitter changes in the adult @entity7 with perinatal XXXX .

answer: @entity12


abstract: The control arm of the phase III VIVIANE ( @entity2 : Vaccine Immunogenicity ANd Efficacy; NCT00294047) study in @entity0 >25 years was studied to assess risk of progression from cervical @entity1 to detectable @entity4 ( @entity4 ). The risk of detecting @entity4 associated with the same HPV type as the reference infection was analysed using Kaplan-Meier and multivariable Cox models. Infections were categorised depending upon persistence as 6-month @entity1 (6MPI) or infection of any duration. The 4-year interim analysis included 2,838 @entity0 , of whom 1,073 (37.8%) experienced 2,615 infections of any duration and 708 (24.9%) experienced 1,130 6MPIs. Infection with oncogenic HPV types significantly increased the risk of detecting @entity4 grade 2 or greater (CIN2+) versus non-oncogenic types. For 6MPI, the highest risk was associated with HPV-33 (hazard ratio [HR]: 31.9 [8.3-122.2, p   <   0.0001]). The next highest risk was with @entity3 (21.1 [6.3-70.0], p   <   0.0001). Similar findings were seen for infections of any duration. Significant risk was also observed for HPV-18, HPV-31, and HPV-45. Concomitant @entity1 or @entity4 grade 1 or greater associated with a different oncogenic HPV type increased risk. Most @entity0 (79.3%) with an @entity1 at baseline cleared detectable infections of any duration, and 69.9% cleared a 6MPI. The risk of progression of @entity1 to CIN2+ in @entity0 >25 years in this study was similar to that in @entity0 15-25 years in PATRICIA.

title: Progression of @entity1 to detectable cervical lesions or clearance in adult XXXX : Analysis of the control arm of the VIVIANE study.

answer: @entity0


abstract: In the present study, we have established Dexter-type long-term cultures (D-LTC) from @entity0 umbilical cord blood (UCB) and followed the kinetics of different @entity1 ( @entity1 )--including multipotent (colony forming unit [CFU]-Mixture), erythroid (CFU-erythroid, BFU-E), and myeloid (CFU-granulocyte, CFU-macrophage, CFU-granulocyte/marcophage) progenitors as well as of morphologically recognizable erythroid, myeloid and lymphoid cells--during a nine-week culture period. D-LTC were also established from adult bone marrow (BM) as controls. On day 0, both UCB and BM showed similar total numbers of @entity1 (about 310/10(5) cells), however, UCB showed a higher proportion of primitive @entity1 (i.e., CFU-Mixture, CFU-granulocyte/macrophage and BFU-E). A poor adherent cell layer, consisting almost exclusively of macrophages, was developed in UCB D-LTC and this correlated with a continuous decline in @entity2 numbers throughout the culture period. In contrast, adherent cell numbers in BM D-LTC, including fibroblasts and macrophages, were two- to fourfold higher than in UCB cultures, and the numbers of @entity1 were also significantly higher, reaching plateau levels between weeks 6 and 9. In both types of cultures, erythroid and multipotent progenitors declined relatively fast, reaching undetectable levels after five weeks of culture. Myeloid progenitors, on the other hand, were sustained longer (always at higher levels in BM cultures) and were still detected by week 9. Among myeloid progenitors, a shift towards the predominance of macrophage @entity1 was observed, both in UCB and BM D-LTC, and this correlated with an increase in the proportion of mature monocytes and macrophages. Taken together, our results indicate that myeloid progenitor cell growth is deficient in UCB D-LTC and suggest that this is due to the impaired development of an adherent cell layer, unable to provide the factors and conditions required for their growth. Interestingly, throughout the culture period the total numbers of multipotent and erythroid progenitors were similar both in UCB and BM cultures regardless of the number and types of adherent cells present; this suggests that the stroma developed in D-LTC is not sufficient for the proliferation of these progenitor cells.

title: Kinetics of hematopoiesis in Dexter-type long-term cultures established from XXXX umbilical cord blood cells.

answer: @entity0


abstract: OBJECTIVE: To assess the association between early anthropometric measurements, device-assisted feeding, and early neurodevelopment in @entity0 with complex @entity2 ( @entity2 ). STUDY DESIGN: Bayley Scales of @entity0 Development II were used to assess cognitive and motor skills in 72 @entity0 with CHD at 6 and 12  months of age. Linear regression models were used to assess the association between mode of feeding and anthropometric measurements with neurodevelopment at 6 and 12  months of age. RESULTS: Of the 72 @entity0 enrolled in the study, 34 (47%) had single-ventricle physiology. The mean @entity1 ( @entity1 ) and @entity3 at 6  months of age were 92      10 and 81      14, respectively. At 12  months of age, the mean @entity1 and @entity3 scores were 94      12 and 80      16, respectively. Lower length-for-age z score (P  <  .01) and head circumference-for-age z score (P  <  .05) were independently associated with lower @entity1 at 6  months, and both increased hospital length of stay (P  <  .01) and lower length-for-age z score (P  =  .04) were associated independently with lower @entity1 at 12  months. Device-assisted feeding at 3  months (P  =  .04) and lower length-for-age z score (P  <  .05) were independently associated with lower @entity3 at 6  months. Both lower weight-for-age z score (P  =  .04) and lower length-for-age z score (P  =  .04) were associated independently with @entity3 at 12  months. CONCLUSION: Neonates with complex CHD who required device-assisted feeding and those with lower weight and length and head circumference z scores at 3  months were at risk for neurodevelopmental delay at 6 and 12  months of age.

title: The Association among Feeding Mode, Growth, and Developmental Outcomes in @entity0 with XXXX at 6 and 12 Months of Age.

answer: @entity2


abstract: PURPOSE: To assess the safety, efficacy of double-sling procedure (DS) for the surgical management of stress @entity1 (SUI) with concomitant anterior wall prolapse (AVWP) and to identify if less synthetic material implantation will decrease the complication rates without decreasing the high cure rates. METHODS: We reviewed the @entity0 who underwent DS in two institutions from January 2009 to December 2013. In DS, there are two transobturator tapes inserted from two different routes for the surgical management of SUI with concomitant AVWP. POP-Q was used for anatomical evaluation of prolapse. SUI was assessed by cough stress test and ICIQ-SF questionnaire. We accepted that the @entity0 was satisfied if the visual analog scale score was >= 80. The severity of @entity1 was classified by ICIQ-SF. The @entity0 were evaluated at the 3 and 12  months and annually. RESULTS: A total of 74 @entity0 met the requirements for inclusion and had sufficient records for analysis. The mean follow-up period was 35.4  months (range 12-60). Operative time was 33.2      6.2. The objective cure and subjective success rates of SUI were 87.8 and 93.2  %, respectively. The satisfaction from the surgery was also high with 86.5  % rate. The anatomical success in our series was rather high with 96  % rate. Our overall complication rate was 12.2  %. Mesh extrusion rate was 0  %. CONCLUSIONS: Double-sling procedure is feasible, efficient, and safe. Reducing the mesh size did not have a detrimental effect on the outcomes of SUI treatment and simultaneous AVWP repair.

title: Double-sling procedure for the surgical management of stress XXXX with concomitant anterior vaginal wall prolapse.

answer: @entity1


abstract: BACKGROUND: The objective of the study was to evaluate the gene expression of inflammatory cytokines (interleukin [IL]-1b, IL-6, IL-8, IL-10, @entity0 @entity1 factor [TNF]-a, IL-1 receptor antagonist [ra] and serum amyloid A (SAA) in endometrial tissue and circulating leukocytes in response to uterine inoculation of 105 colony forming units (CFU) @entity2 in mares. Before inoculation, mares were classified as resistant or susceptible to persistent @entity3 based on their uterine inflammatory response to infusion of 109 killed spermatozoa and histological assessment of the endometrial quality. Endometrial biopsies were obtained 3, 12, 24 and 72 hours (h) after bacterial inoculation and blood samples were obtained during the 7 day period post bacterial inoculation. Expression levels of cytokines and SAA were determined by quantitative real-time reverse transcriptase PCR (qRT-PCR). RESULTS: Compared to levels in a control biopsy (obtained in the subsequent estrous), resistant mares showed an up-regulation of IL-1b, IL-6, IL-8 and TNF-a at 3 h after @entity2 inoculation, while susceptible mares showed increased gene expression of IL-6 and IL-1ra. Susceptible mares had a significant lower gene expression of TNF-a,IL-6 and increased expression of IL-1ra 3 h after @entity2 inoculation compared to resistant mares. Susceptible mares showed a sustained and prolonged inflammatory response with increased gene expression levels of IL-1b, IL-8, IL-1ra and IL-1b:IL-1ra ratio throughout the entire study period (72 h), whereas levels in resistant mares returned to estrous control levels by 12 hours. Endometrial mRNA transcripts of IL-1b and IL-1ra were significantly higher in mares with heavy uterine bacterial growth compared to mares with no/mild growth.All blood parameters were unaffected by intrauterine @entity2 infusion, except for a lower gene expression of IL-10 at 168 h and an increased expression of IL-1ra at 48 h observed in susceptible mares compared to resistant mares. CONCLUSIONS: The current investigation suggests that endometrial mRNA transcripts of pro-inflammatory cytokines in response to @entity3 are finely regulated in resistant mares, with initial high expression levels followed by normalization within a short period of time. Susceptible mares had a prolonged expression of pro-inflammatory cytokines, supporting the hypothesis that an unbalanced endometrial gene expression of inflammatory cytokines might play an important role in the pathogenesis of persistent @entity3 .

title: Inflammatory responses to induced @entity3 in mares resistant or susceptible to persistent XXXX .

answer: @entity3


abstract: @entity5 ( @entity5 ) or single central incisor is a @entity8 . It has been reported in @entity11 ( @entity11 ) cases with severe @entity1 or as a microform in autosomal dominant @entity11 (ADHPE). In our review of the literature, we note that @entity5 may also occur as an isolated finding or in association with other @entity6 . These anomalies include @entity3 , @entity9 , @entity7 , @entity12 , @entity2 , and congenital nasal pyriform aperture @entity2 . @entity5 can also be a feature of recognized syndromes or associations or a finding in @entity0 with specific @entity4 . We performed a molecular study on a cohort of 13 @entity5 @entity0 who did not have @entity11 . We studied two genes, @entity10 and @entity13 , in which mutations have been reported in @entity0 showing @entity5 as part of the @entity11 spectrum. A new missense mutation in @entity10 ( @entity14 ), segregating in one @entity5 family, was identified. Our results suggest that this mutation may be specific for the @entity5 phenotype since it has not been found in the @entity11 population or in normal controls. Published 2001 Wiley-Liss, Inc.

title: @entity10 mutation is associated with solitary median maxillary central incisor: a study of 13 XXXX and review of the literature.

answer: @entity0


abstract: UNASSIGNED: The role of post-mastectomy radiotherapy for pT3N0 @entity0 remains undefined. The purpose of this study was to report institutional outcomes for @entity1 with pT3N0 @entity0 treated with and without post-mastectomy radiotherapy. We collected data from two large @entity2 registries on pT3N0 @entity0 diagnosed between 1985 and 2014. Kaplan-Meier estimates were used to analyze freedom from local-regional recurrence (FFLR), relapse free survival, and overall survival. This analysis identified 93 @entity1 with pT3N0 @entity0 . Of these, 53 received post-mastectomy radiotherapy and 40 did not. Median follow-up was 6.2 years and 5.3 years in the non-post-mastectomy radiotherapy and post-mastectomy radiotherapy cohorts, respectively. @entity1 not undergoing post-mastectomy radiotherapy were more likely to be diagnosed in the 1980s and 1990s and were less likely to receive systemic therapies than @entity1 receiving post-mastectomy radiotherapy (p < 0.05). There was a trend toward increased FFLR in the @entity1 receiving post-mastectomy radiotherapy (p = 0.15). FFLR in the post-mastectomy radiotherapy cohort was 98% at both 5 and 10 years. For @entity1 not receiving post-mastectomy radiotherapy, FFLR was 88% at both 5 and 10 years. @entity1 not receiving post-mastectomy radiotherapy in our study had an isolated local-regional failure rate of 12% at 10 years, despite receiving inferior systemic treatment by current standards. Local-regional control after post-mastectomy radiotherapy for pT3N0 @entity0 was excellent. Further research is needed to define post-mastectomy radiotherapy indications for this @entity1 population when receiving chemotherapy and endocrine therapy in line with current guidelines.

title: Post-mastectomy Radiotherapy for pT3N0 XXXX : A Retrospective, Multi-Institution Review.

answer: @entity0


abstract: OBJECTIVE: To investigate the relationship between esophageal function and the extent of disease in a nonselected group of @entity3 @entity0 , and to study gastric and small bowel motility in a group of @entity3 @entity0 with more severe clinical manifestations. METHODS: Esophageal function in 125 @entity3 @entity0 was investigated by radiologic, endoscopic, manometric, and pH-metric techniques. Ten @entity0 also underwent gastrointestinal (GI) manometric recording, both during fasting and after a standard meal. RESULTS: Radiologic abnormalities of the esophagus were found in 55 of 81 @entity0 (68%) and @entity4 in 45 of 125 (36%). No significant relationship was disclosed between GI symptoms, @entity1 , @entity4 grade, and the various disease subsets. However, the overall incidence of endoscopic @entity4 (irrespective of the degree) was significantly (P < 0.05) correlated with the @entity0 subgroups, with 100% incidence of @entity4 in those having the more severe cutaneous involvement (type III). @entity1 were documented in 80% of @entity0 , and pathologic reflux in 78%. The severity of @entity2 on manometry significantly correlated with the severity of the disease, whereas no correlations were found with pH-metric data. Ninety percent of the 10 female @entity0 undergoing antroduodenal manometry displayed abnormal findings; of these, 60% showed neuropathic, and 30% myopathic, patterns. The latter were recorded in @entity0 with a more severe stage of the disease (type III). CONCLUSION: A direct relationship was observed between @entity3 subsets and the severity of esophageal (and, probably, more distal gut) motor involvement. Since no correlation was found between esophageal symptoms and the severity of @entity1 , manometry should be considered the single most important GI test to document the severity of the "esophageal" disease. Gastric and small bowel manometry may also offer evidence of widespread gut involvement, and provide a rationale for a more targeted therapeutic approach.

title: XXXX in @entity3 : relationship with disease subsets.

answer: @entity2


abstract: T cell activation is controlled by the coordination of stimulatory and negative regulatory signals which are not completely defined. In this study we tested for a possible direct effect of @entity9 on the regulation of T cell activation and function. We show that soluble @entity9 (sCD14) induces inhibition of antigen-mediated peripheral blood mononuclear cells (PBMC) proliferation and anti-CD3-mediated proliferation of @entity2 + @entity3 +, @entity2 + @entity3 + and @entity2 + @entity3 + Tcell clones. This effect is not due to cell death, but results from a marked inhibition of @entity5 production. @entity6 cell clones due to exogenous @entity5 is not affected by sCD14. We also found that sCD14 inhibits production of another @entity4 -like cytokine, @entity1 and a Th2-like cytokine, @entity7 . Importantly, sCD14 induces a progressive accumulation of the inhibitory protein @entity8 . We show that sCD14 binds to activated T cells. Following cell activation, biotinylated sCD14 stains CD3+ PBMC, as well as @entity0 T cell clones with varying intensity. The binding is saturable, can be inhibited by excess of unlabeled sCD14 and, following binding, sCD14 is internalized. Collectively, these findings reveal a previously unrecognized function of sCD14, namely its capacity to negatively regulate T lymphocyte activation and function by interacting directly with activated T cells.

title: Soluble @entity9 acts as a negative regulator of XXXX T cell activation and function.

answer: @entity0


abstract: AIMS: We studied the relationship of @entity4 ( @entity4 ) measured at 15 specified body sites with @entity3 before and after a weight loss program for three weeks. SUBJECTS AND METHODS: In 70 @entity1 @entity0 , @entity4 were measured by means of the optical device, lipometer. Fat mass (FM) was estimated by means of bioelectrical impedance. RESULTS: At the beginning of the study, all estimates of @entity4 , insulin, and @entity4 from the upper body (from 1-neck to 6-lateral chest) were correlated to @entity3 at a P-value of<0.0001. Percentage FM together with @entity2 and insulin explained 75% of the variation in @entity3 (P<0.0001). After three weeks, estimates of @entity4 and @entity3 were reduced (all P<0.0001). Most @entity4 were reduced, but @entity4 8-lower abdomen and 9-lower back were significantly increased. Changes in @entity3 were best explained by initial @entity3 , but percentage change (Delta) in insulin, Delta SAT-layer 1-neck, and Delta SAT-layer 3-biceps contributed to the Delta @entity3 (adj. r(2)=0.47, P<0.0001). In the weight-reduced state, circulating @entity3 was best explained by three @entity4 and insulin (adj. r(2)=0.67, P<0.0001). DISCUSSION: The results suggest that Delta changes in @entity3 are attributable to changes in the endocrine state and subcutaneous fat, and @entity4 may serve as a stable correlate of @entity3 in the weight-reduced state.

title: Subcutaneous adipose tissue layers as a stable correlate of @entity3 in response to short term energy restriction in @entity1 XXXX .

answer: @entity0


abstract: PURPOSE: To evaluate the efficacy of @entity2 0.7mg intravitreal implant in @entity0 with @entity4 . MATERIALS AND METHODS: Fourteen @entity0 ' charts with @entity4 were retrospectively reviewed. The main outcome measures were best-corrected visual acuity (BCVA) and mean @entity3 ( @entity3 ). RESULTS: @entity0 ' mean age was 72.1  years old. Five @entity0 were @entity1 . All @entity0 had previously been treated with non-steroidal anti-inflammatory drops. Four @entity0 had received a previous treatment with intravitreal ranibizumab. The mean follow-up period was 8.7  months. Mean BCVA before intravitreal @entity2 was 0.72  logMAR. After injection, it improved to 0.50  at month 1, was 0.47  at month 3, and 0.60  logMAR at month 12. The pre-injection mean @entity3 was 598 m. It improved to 286 m at month 1, 338 m at month 3, and was 441 m at month 12. Eight @entity0 received 2  intravitreal injections of @entity2 . Five @entity0 presented with elevated intraocular pressure during follow-up, which was treated with drops. CONCLUSIONS: Intravitreal @entity2 injection improved visual acuity and macular thickness at month 1  and month 3  in @entity0 with @entity4 . A second injection was necessary after a mean period of 5  months.

title: [Treatment of XXXX ( @entity4 ) with @entity2 0.7mg intravitreal implant].

answer: @entity4


abstract: OBJECTIVE: To evaluate the association between @entity4 and survival in @entity0 with @entity1 treated with primary chemoradiation. METHODS: A single institution, retrospective analysis of @entity0 with stage @entity5 -IVA @entity1 who received upfront chemoradiation from 1998 to 2013 was performed. Complete blood counts from pre-treatment to 36months post-treatment were analyzed. @entity4 and known prognostic factors were evaluated for an association with progression-free (PFS) and overall survival (OS). RESULTS: Seventy-one @entity0 met study criteria for whom 47 (66%) had a documented @entity3 ( @entity3 ) two months after initiating chemoradiation. FIGO stage distribution was 6% Stage I, 46% Stage II, 45% Stage III and 3% Stage IV. Pre-treatment @entity3 was abnormal (<1000 cells/mm(3)) in 15% of @entity0 . The mean reduction in @entity3 was 70% two months after initiating chemoradiation. Severe post-treatment @entity4 ( @entity3 <500cells/mm(3)) was observed in 53% of @entity0 ; they experienced inferior median OS (21.2 vs 45.0months, P=0.03) and similar 25th percentile PFS (6.3 vs 7.7months, P=0.06) compared to @entity0 without severe @entity4 . Multivariate analysis demonstrated pre-treatment @entity3 >= 1000cells/mm(3) and post-treatment @entity3 >500cells/mm(3) had a 77% (HR: 0.23; 95%CI 0.05-1.03; P=0.053) and 58% decrease in hazards of @entity2 (HR: 0.42; 95%CI 0.12-1.46; P=0.17) respectively. CONCLUSION: More than half of @entity1 @entity0 treated with chemoradiation experienced severe and prolonged @entity4 . Although statistical significance was not reached, the findings suggest that pre- and post-treatment @entity4 may be associated with decreased survival. Further research is warranted, given that @entity4 could be a reversible prognostic factor.

title: @entity4 and its association with survival in XXXX with locally advanced @entity1 .

answer: @entity0


abstract: OBJECTIVE: To observe the effect of acupuncture combined physical training and relearning on @entity2 @entity0 . METHODS: A multi-center, randomized controlled trial design was adopted. A total of 364 @entity2 @entity0 were recruited and randomly assigned to the experimental group (184 cases) and the control group (180 cases). @entity0 in the experimental group received acupuncture combined with physical training and relearning, while those in the control group only received physical training and relearning. All received four weeks of treatment. Effects on Fugl-Meyer motor function, @entity1 , activities of daily living difference were compared before treatment, after treatment, 2 and 5 months after follow-ups between the two groups. RESULTS: Totally 353 @entity0 completed this trial, 179 in the experimental group and 174 in the control group. (1) compared with before treatment, brief Fugl-Meyer motor functions scores and @entity3 scored obviously increased, and scores for @entity1 obviously decreased in the two group. Besides, the increment of brief Fugl-Meyer motor functions scores and @entity3 scores was obviously higher in the experimental group than in the control group at month 2 and 5 of follow-ups; scores for @entity1 was obviously lower in the experimental group than in the control group. The increment of @entity3 scores was obviously higher in the experimental group than in the control group at month 5 of follow-ups (P < 0.05, P < 0.01). (2) There was statistical difference in inter-group comparison of total Fugl-Meyer motor functions scores and @entity3 scores, or scores for @entity1 (P < 0.01). The improvement of Fugl-Meyer motor functions grading and @entity1 grading was obviously superior in the experimental group at month 2 and 5 of follow-ups. The distribution of @entity3 grading was also better in the experimental group at month 5 of follow-ups (P < 0.05, P < 0. 01). CONCLUSIONS: Both acupuncture combined exercise training and relearning and physical training and relearning could effectively promote the rehabilitation of @entity2 @entity0 , reduce their @entity1 degrees, improve motor functions and independent capacities. Better long-term efficacy could be obtained by acupuncture combined exercise training and relearning.

title: [Effect of Acupuncture Combined Physical Training and Relearning on XXXX Rehabilitation: a Multi-center Randomized Controlled Clinical Study].

answer: @entity2